Inovio Pharmaceuticals, Inc. (INO) Q1 2023 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET

Company Participants

Thomas Hong - Manager of Investor Communications
Jacqueline Shea - President and Chief Executive Officer
Michael Sumner - Chief Medical Officer
Peter Kies - Chief Financial Officer

Conference Call Participants

Hartaj Singh - Oppenheimer
Li Chen - H.C. Wainwright

Operator

Good day and welcome to the Inovio First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode for the duration of the call. [Operator Instructions] After today's presentation there will be an opportunity to ask questions. [Operator Instructions] Please also note that this event is being recorded today.

I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead.

Thomas Hong

Good afternoon and thank you for joining the Inovio 2023 first quarter conference Call. Joining me on today's call are Dr. Jacque Shea, President and CEO; Dr. Michael Sumner, Chief Medical Officer; and Mr. Peter Kies, Chief Financial Officer. We also have other members of Innovia's leadership here with us today, who will be part of our Q&A session.

Today's call will review our corporate and financial information for the quarter ended March 31, 2023, as well as provide a development and progress update for our DNA medicines platform. Following prepared remarks, we will conduct a question-and-answer segment.

During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Inovio's DNA medicines platform, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters. All of these statements are based on the beliefs and expectations of management as of today.

Actual events or results